Sotac Pharmaceuticals (NSE:SOTAC) EBIT: ₹150.5 Mil (TTM As of Sep. 2025)


NSE:SOTAC Sotac Pharmaceuticals Ltd NSE:SOTAC
53 GF Score
Price ₹105.00
GF Value ₹110.01
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Sotac Pharmaceuticals EBIT?

Sotac Pharmaceuticals NSE:SOTAC 53 EBIT is ₹150.5 Mil as of Sep. 2025. GuruFocus rates NSE:SOTAC with a GF Score™ of 53/100 and a GF Value™ of ₹110.01 (Fairly Valued). The stock has 6 warning signs investors should review.

Sotac Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was ₹52.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹150.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sotac Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2025 was 1.43%. Sotac Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 11.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sotac Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 9.56%.

Sotac Pharmaceuticals  (NSE:SOTAC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sotac Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=18.882 * ( 1 - 22.75% )/( (1031.132 + 1002.811)/ 2 )
=14.586345/1016.9715
=1.43 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1243.282 - 194.191 - ( 17.959 - max(0, 515.49 - 698.274+17.959))
=1031.132

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1232.695 - 207.883 - ( 22.001 - max(0, 527.006 - 705.511+22.001))
=1002.811

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sotac Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=104.576/( ( (469.712 + max(459.877, 0)) + (462.2 + max(439.703, 0)) )/ 2 )
=104.576/( ( 929.589 + 901.903 )/ 2 )
=104.576/915.746
=11.42 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(341.122 + 202.609 + 136.584) - (194.191 + 0 + 26.247)
=459.877

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(327.435 + 192.364 + 158.573) - (207.883 + 0 + 30.786)
=439.703

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sotac Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=150.462/1573.811
=9.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals EBIT Related Terms

Sotac Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Sotac Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals EBIT Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial -10.61 0.00 58.28 55.15 133.53

Sotac Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.98 24.17 35.35 98.17 52.29

NSE:SOTAC vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sotac Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sotac Pharmaceuticals's EV-to-EBIT falls into.


NSE:SOTAC
53GF Score
Sotac Pharmaceuticals Ltd NSE:SOTAC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sotac Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹150.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹150.5 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a EBIT of ₹150.5 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sotac Pharmaceuticals.
Is Sotac Pharmaceuticals' EBIT too high?
Sotac Pharmaceuticals' current EBIT is ₹150.5 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' EBIT compare to ZTS?
Sotac Pharmaceuticals' EBIT of ₹150.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sotac Pharmaceuticals. Sotac Pharmaceuticals's current EBIT is ₹150.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Fairly Valued. The stock's GF Value™ is ₹110.01, compared to a current price of ₹105.00 — trading 4.6% below its estimated fair value. The current EBIT is ₹150.5 Mil. Sotac Pharmaceuticals' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current EBIT is ₹150.5 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued. The current stock price of ₹105.00 is trading 4.6% below its estimated GF Value™ of ₹110.01. GuruFocus considers Sotac Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:SOTAC:

  • EBIT: ₹150.5 Mil
  • GF Value™: ₹110.01 vs. price of ₹105.00 (4.6% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotac Pharmaceuticals Business Description

Address Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
53GF Score

Get the complete analysis for NSE:SOTAC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹105.00
Price
₹110.01
GF Value